These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26766804)

  • 41. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
    Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
    Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.
    Traish AM; Hassani J; Guay AT; Zitzmann M; Hansen ML
    J Sex Med; 2011 Mar; 8(3):872-84. PubMed ID: 21176115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
    Corona G; Rastrelli G; Maseroli E; Balercia G; Sforza A; Forti G; Mannucci E; Maggi M
    J Endocrinol Invest; 2012 Nov; 35(10):915-20. PubMed ID: 22777612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of rhabdomyolysis from 5-α reductase inhibitors.
    Welk B; McArthur E; Ordon M; Dirk J; Dixon S; Garg AX
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):351-355. PubMed ID: 29368380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia.
    Alcántara Montero A; Müller-Arteaga C
    Actas Urol Esp (Engl Ed); 2019; 43(1):52-53. PubMed ID: 30032935
    [No Abstract]   [Full Text] [Related]  

  • 46. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
    Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
    J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study.
    Matsumoto T; Hatakeyama S; Narita T; Yoneyama T; Hashimoto Y; Ohyama C
    Int J Urol; 2019 Apr; 26(4):522-523. PubMed ID: 30659664
    [No Abstract]   [Full Text] [Related]  

  • 48. 5α-reductase inhibitors impact prognosis of urothelial carcinoma.
    Wang CS; Li CC; Juan YS; Wu WJ; Lee HY
    BMC Cancer; 2020 Sep; 20(1):872. PubMed ID: 32917158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
    Seale LR; Eglini AN; McMichael AJ
    J Drugs Dermatol; 2016 Apr; 15(4):414-9. PubMed ID: 27050696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.
    Boyapati A; Sinclair R
    Australas J Dermatol; 2013 Feb; 54(1):49-51. PubMed ID: 22686691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
    Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
    JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistent sexual side effects of finasteride for male pattern hair loss.
    Irwig MS; Kolukula S
    J Sex Med; 2011 Jun; 8(6):1747-53. PubMed ID: 21418145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hormonal manipulation of benign prostatic hyperplasia.
    Rick FG; Saadat SH; Szalontay L; Block NL; Kazzazi A; Djavan B; Schally AV
    Curr Opin Urol; 2013 Jan; 23(1):17-24. PubMed ID: 23202285
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of Association between 5α-Reductase Inhibitors and Depression.
    Dyson TE; Cantrell MA; Lund BC
    J Urol; 2020 Oct; 204(4):793-798. PubMed ID: 32294395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain.
    Motofei IG; Rowland DL; Manea M; Georgescu SR; Păunică I; Sinescu I
    Clin Drug Investig; 2017 Jun; 37(6):511-517. PubMed ID: 28161756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia?
    Motofei IG; Rowland DL; Georgescu SR; Tampa M; Baleanu BC; Paunica S
    Exp Dermatol; 2016 Jul; 25(7):557-8. PubMed ID: 26990657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dutasteride for the treatment of prostate-related conditions.
    Slater S; Dumas C; Bubley G
    Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atypical post-finasteride syndrome: A pharmacological riddle.
    Gupta AK; Sharma N; Shukla P
    Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 'Post-finasteride syndrome': what to tell our female patients?
    Mervis JS; Borda LJ; Miteva M
    Br J Dermatol; 2018 Sep; 179(3):785-786. PubMed ID: 29624646
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.